

S. 1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

As reported by the Senate Committee on Health, Education, Labor, and Pensions on September 6, 2023

By Fiscal Year, Millions of Dollars	2024	2024-2029	2024-2034
Direct Spending (Outlays)	0	0	0
Revenues	0	0	0
Increase or Decrease (-) in the Deficit	0	0	0
Spending Subject to Appropriation (Outlays)	0	32	32
Increases <i>net direct spending</i> in any of the four consecutive 10-year periods beginning in 2035?	No	Statutory pay-as-you-go procedures apply?	No
		Mandate Effects	
Increases <i>on-budget deficits</i> in any of the four consecutive 10-year periods beginning in 2035?	No	Contains intergovernmental mandate?	No
		Contains private-sector mandate?	No

S. 1852 would reauthorize the appropriation of \$8 million each year from 2024 through 2028 for the Centers for Disease Control and Prevention and the Health Resources and Services Administration to conduct research, surveillance, prevention, and treatment of sickle cell disease and related blood disorders. In 2024, \$8 million was allocated for these purposes; therefore, CBO estimates the bill would authorize no additional funding for 2024.

Based on historical spending patterns for those activities and assuming the appropriation of the authorized amounts, CBO estimates that implementing the bill would cost \$32 million over the 2024-2029 period.

The costs of the legislation, detailed in Table 1, fall within budget function 550 (health).

Table 1.
Estimated Increases in Spending Subject to Appropriation Under S. 1852

	By Fiscal Year, Millions of Dollars						2024-2029
	2024	2025	2026	2027	2028	2029	
Authorization	0	8	8	8	8	0	32
Estimated Outlays	0	5	8	8	8	3	32

See also

[CBO's Cost Estimates Explained](#), [CBO Describes Its Cost-Estimating Process](#), [Glossary](#)



On January 3, 2024, CBO transmitted a [cost estimate for H.R. 3884](#), the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023, as reported by the House Committee on Energy and Commerce on August 25, 2023. The two bills are similar. However, CBO's estimate for S. 1852 incorporates funding allocated in 2024 and an updated projection period.

The CBO staff contact for this estimate is Lily Johnson. The estimate was reviewed by Emily Stern, Senior Adviser for Budget Analysis.

A handwritten signature in black ink that reads "Phillip L. Swagel". The signature is fluid and cursive, with a long, sweeping underline.

Phillip L. Swagel
Director, Congressional Budget Office